TNXP

NASDAQ · Biotechnology

Tonix Pharmaceuticals Holdin

Stocks Under $10 Biotech Stocks Healthcare Stocks

$9.74

-0.16 (-1.62%)

As of Sep 29, 2:35 PM ET ·

TNXP News1 articles

Tonix Pharma Surges on Promising Lyme Antibody Data; Phase 2 Trial Eyed for 2027

Tonix Pharmaceuticals shares rose after new Phase 1 modeling data for its Lyme antibody TNX-4800 showed six-month protection with two doses. A Phase 2 trial is targeted for 2027.